Literature DB >> 19401618

Mechanisms of M3 muscarinic receptor regulation by wash-resistant xanomeline binding.

Meredith J Noetzel1, Marianne K O Grant, Esam E El-Fakahany.   

Abstract

BACKGROUND/AIMS: Xanomeline has been shown to bind in a unique manner at M1 and M3 muscarinic receptors, with interactions at both the orthosteric site and an allosteric site. We have previously shown that brief exposure of Chinese hamster ovary cells that express the M3 receptor to xanomeline followed by removal of free agonist results in a delayed decrease in radioligand binding and receptor response to agonists. In the current study, we were interested in determining the mechanisms of this effect.
METHODS: Cells were treated with carbachol, pilocarpine or xanomeline for 1 h followed by washing and either used immediately or after waiting for 23 h. Control groups included cells that were not exposed to agonists and cells that were treated with agonists for 24 h. Radioligand binding and functional assays were conducted to determine the effects of agonist treatments.
RESULTS: The above treatment protocol with xanomeline resulted in similar effects of the binding of [(3)H]NMS and [(3)H]QNB. When receptor function is blocked using a variety of methods, the long-term effects of xanomeline binding were absent.
CONCLUSION: Our data indicate that xanomeline wash-resistant binding at the receptor allosteric site leads to receptor downregulation and that receptor activation is necessary for these effects. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401618      PMCID: PMC2835379          DOI: 10.1159/000214843

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  40 in total

Review 1.  Molecular mechanisms of regulation of neuronal muscarinic receptor sensitivity.

Authors:  E E el-Fakahany; C L Cioffi
Journal:  Membr Biochem       Date:  1990 Jan-Mar

2.  Agonist-induced down-regulation of m1 muscarinic receptors and reduction of their mRNA level in a transfected cell line.

Authors:  S Z Wang; J R Hu; R M Long; W S Pou; C Forray; E E el-Fakahany
Journal:  FEBS Lett       Date:  1990-12-10       Impact factor: 4.124

3.  Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.

Authors:  F J Ehlert
Journal:  Mol Pharmacol       Date:  1988-02       Impact factor: 4.436

4.  Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.

Authors:  W Lee; B B Wolfe
Journal:  Mol Pharmacol       Date:  1989-11       Impact factor: 4.436

5.  Regulation of muscarinic cholinergic receptor density in neuroblastoma cells by brief exposure to agonist: possible involvement in desensitization of receptor function.

Authors:  P Feigenbaum; E E El-Fakahany
Journal:  J Pharmacol Exp Ther       Date:  1985-04       Impact factor: 4.030

6.  Temperature dependence of muscarinic acetylcholine receptor activation, desensitization, and resensitization.

Authors:  E El-Fakahany; E Richelson
Journal:  J Neurochem       Date:  1980-05       Impact factor: 5.372

7.  Relationship between agonist-induced muscarinic receptor loss and desensitization of stimulated phosphoinositide turnover in two neuroblastomas: methodological considerations.

Authors:  A K Thompson; S K Fisher
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

8.  Selectivity of McN-A-343 in stimulating phosphoinositide hydrolysis mediated by M1 muscarinic receptors.

Authors:  J R Hu; E E el-Fakahany
Journal:  Mol Pharmacol       Date:  1990-12       Impact factor: 4.436

9.  Differential sensitivity of phosphoinositide and cyclic GMP responses to short-term regulation by a muscarinic agonist in mouse neuroblastoma cells. Correlation with down-regulation of cell surface receptors.

Authors:  C L Cioffi; E E el-Fakahany
Journal:  Biochem Pharmacol       Date:  1989-06-01       Impact factor: 5.858

10.  Muscarinic receptor: regulation by guanine nucleotides, ions, and N-ethylmaleimide.

Authors:  F J Ehlert; W R Roeske; H I Yamamura
Journal:  Fed Proc       Date:  1981-02
View more
  3 in total

Review 1.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

2.  3-[3-(3-florophenyl-2-propyn-1-ylthio)-1, 2, 5-thiadiazol-4-yl]-1, 2, 5, 6-tetrahydro-1- methylpyridine oxalate, a novel xanomeline derivative, improves neural cells proliferation and survival in adult mice.

Authors:  Xiaoliang Zhang; Qiang Gong; Shuang Zhang; Lin Wang; Yinghe Hu; Haiming Shen; Suzhen Dong
Journal:  Neural Regen Res       Date:  2012-01-05       Impact factor: 5.135

3.  Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.

Authors:  Eva Šantrůčková; Vladimír Doležal; Esam E El-Fakahany; Jan Jakubík
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.